ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset
VANCOUVER, British Columbia — ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced an extension to its option agreement to license the National Research Council of Canada’s (NRC) proprietary nanobody-based CD22 binder for use […]
Read original article on Financial Post →Related news
- It’s ‘what jihadists do’: Plan to livestream U.S. military firing squad execution draws criticism
-
Crackdown on seatbelts, distracted driving sees number of tickets double in B.C.
- Island Passage Trenching Confirms Porphyry Copper-Gold System at the EL02 Project, Bougainville Island, Papua New Guinea
-
What’s next for Edmonton infill housing after province orders rule reversal?
-
Collaros returns from head injury as Blue Bombers face Stampeders in crucial clash
-
Accused in lengthy Kingston sexual assault trial begins defence
-
Powerful 7.7 magnitude earthquake rocks Panama
-
Klein pitches new advanced-care paramedic teams to tackle low-acuity calls in Winnipeg